Search Results 971-980 of 16366 for monoclonal antibody

  1. Immune globulin-stwk (intravenous route) - Mayo Clinic

    Description. Immune globulin-stwk injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral ...

  2. A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

    Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown. Anti-immunoglobulin E (IgE) therapy ...

  3. Publications - Pierre Noel, M.D. - Mayo Clinic

    Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004 Apr 15 ...

  4. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) - Mayo Clinic

    Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 ...

  5. A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS) - Mayo Clinic

    History of severe hypersensitivity reaction to any monoclonal antibody. Other severe acute or chronic medical (including bone marrow suppressive diseases) ...

  6. A Study of AP160-Complex in Advanced Solid Tumors - Mayo Clinic

    STI-3031, a fully human anti-PDL1 recombinant monoclonal Ab, will be supplied by Sorrento. ... antibody do not count). Exclusion Criteria. Any of ... Anti-PD(L)1 ...

  7. Center for Multiple Sclerosis and Autoimmune Neurology - Mayo Clinic Research

    ... antibody, the first diagnostic biomarker for any MS-like illness. The discovery that patients with neuromyelitis optica have an autoantibody that targets a ...

  8. Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients - Mayo Clinic

    Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.

  9. Efgartigimod alfa-fcab (intravenous route) - Mayo Clinic

    ... antibody positive. This medicine is to be given only by or under the direct supervision of your doctor. This product is available in the following dosage ...

  10. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

    Have received any monoclonal antibody therapy directed at treatment of the patient's malignancy within 2 weeks prior to anticipated first dose. Have ...